Pfizer Reports Fourth Quarter & Full Year 2016 Results -- Provides 2017 Financial Guidance

Pfizer Inc. press release ----- On Tuesday January 31, 2017 -- Pfizer Inc. (NYSE: PFE) reported financial results for fourth quarter and full-year 2016 and provided 2017 financial guidance. Full-Year 2016 Revenues of $52.8 billion, reflecting 11% Operational growth; Full-Year 2016 Revenues for Pfizer Standalone (Excluding Legacy Hospira and Legacy Medivation) of $48.1 billion, reflecting 5% Operational Growth Fourth-Quarter 2016 Revenues of $13.6 billion, reflecting 1% Operational Decline, Unfavorably impacted by four fewer U.S. selling days and three fewer international selling days compared to the prior year quarter; fourth-quarter 2016 Pfizer standalone revenues of $12.3 billion, reflecting 2% operational decline full-year 2016 reported Diluted EPS of $1.17, Adjusted Diluted EPS of $2.40; fourth-quarter 2016 Reported Diluted EPS of $0.13, Adjusted Diluted EPS of $0.47 provides 2017 Financial Guidance, including revenues of $52.0 to $54.0 billion and Adjusted Diluted EPS of $2.50 to $2.60; reflects pending disposition of Hospira Infusion Systems, which contributed to $1.2 billion of revenues and $0.03 of Adjusted Diluted EPS in 2016. To learn more about Pfizer's Fourth Quarter and full year 2016 results and 2017 financial guidance click on the picture below to read the complete release.